Adolescent anovulation: Maturational mechanisms and implications

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 9, 2013, Pages 3572-3583

  Rosenfield, Robert L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GONADOTROPIN; LEVONORGESTREL; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SEX HORMONE;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ANDROGEN BLOOD LEVEL; ANOVULATION; ARTICLE; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INSULIN RESISTANCE; LUTEAL PHASE; MENSTRUAL CYCLE; MENSTRUATION DISORDER; NEUROENDOCRINE SYSTEM; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PUBERTY DISORDERS; VENOUS THROMBOEMBOLISM; FEMALE; HYPOPHYSIS; OVARY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADOLESCENT; ANOVULATION; FEMALE; HUMANS; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; OVARY; PITUITARY GLAND; POLYCYSTIC OVARY SYNDROME;

EID: 84883731811     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1770     Document Type: Article

References (132)

1. Treloar AE, Boynton RE, Benn BG, BrownBW.Variation ofhuman menstrual cycle through reproductive life. Int J Fertil. 1967;12:77-126.
2. Vollman RF. The menstrual cycle. Major Probl Obstet Gynecol. 1977;7:1-193.
3. Apter D, Vihko R. Hormonal patterns of the first menstrual cycles. In: Venturoli S, Flamigni C, Givens JR, eds. Adolescence in Females. Chicago, IL: Year Book Medical Publishers; 1985:215-238.
4. American Academy of Pediatrics Committee on Adolescence; American College of Obstetricians and Gynecologists Committee on Adolescent Health Care; Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006;118:2245-2250.
5. Legro RS, Lin HM, Demers LM, Lloyd T. Rapid maturation of the reproductive axis during perimenarche independent of body composition. J Clin Endocrinol Metab. 2000;85:1021-1025.
6. Apter D, Vihko R. Serum pregnenolone, progesterone, 17- hydroxyprogesterone, testosterone, and 5-dihydrotestosterone during female puberty. J Clin Endocrinol Metab. 1977;45:1039-1048.
7. Metcalf MG, Skidmore DS, Lowry GF, Mackenzie JA. Incidence of ovulation in the years after the menarche. J Endocrinol. 1983;97: 213-219.
8. Ross GT, Cargille CM, Lipsett MB, et al. Pituitary and gonadal hormones in women during spontaneous and induced ovulatory cycles. Recent Prog Horm Res. 1970;26:1-62.
9. Moghissi KS, Syner FN, Evans TN. A composite picture of the menstrual cycle. Am J Obstet Gynecol. 1972;114:405-418.
10. McNeely MJ, Soules MR. The diagnosis of luteal phase deficiency: a critical review. Fertil Steril. 1988;50:1-15.
11. Soules MR, McLachlan RI, Ek M, Dahl KD, Cohen NL, Bremner WJ. Luteal phase deficiency: characterization of reproductive hormones over the menstrual cycle. J Clin Endocrinol Metab. 1989;69: 804-812.
12. Daya S. Optimal time in the menstrual cycle for serum progesterone measurement to diagnose luteal phase defects.AmJ Obstet Gynecol. 1989;161:1009-1011.
13. Zhang K, Pollack S, Ghods A, et al. Onset of ovulation after menarche in girls: a longitudinal study. J Clin Endocrinol Metab. 2008; 93:1186-1194.
14. Gray SH, Ebe LK, Feldman HA, et al. Salivary progesterone levels before menarche: a prospective study of adolescent girls. J Clin Endocrinol Metab. 2010;95:3507-3511.
15. Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril. 2008;90(5 suppl):S219-S225.
16. Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29:383-390.
17. Munro MG, Critchley HO, Fraser IS. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril. 2011;95:2204-2208,e1-e3.
18. Southam AL, Richart EM. The prognosis for adolescents with menstrual abnormalities. Am J Obstet Gynecol. 1966;94:637-645.
19. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-Amenorrhoea at age 18 years. Hum Reprod. 2004; 19:383-392.
20. Shaw ND, Butler JP, McKinney SM, Nelson SA, Ellenbogen JM, Hall JE. Insights into puberty: the relationship between sleep stages and pulsatile LH secretion. J Clin Endocrinol Metab. 2012;97: E2055-E2062.
21. Tanner JM. Growth at adolescence. London: Blackwell; 1962.
22. Rosenfield RL, Bordini B, Yu C. Comparison of detection of normal puberty in girls by a hormonal sleep test and a gonadotropin-releasing hormone agonist test. J Clin Endocrinol Metab. 2013;98:1591-1601.
23. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53-88.
24. Apter D, Butzow TL, LaughlinGA,Yen SS. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins. J Clin Endocrinol Metab. 1993;76:940-949.
25. March CM, Goebelsmann U, Nakamura RM, Mishell DR Jr. Roles of estradiol and progesterone in eliciting the midcycle luteinizing hormone and follicle-stimulating hormone surges. J Clin Endocrinol Metab 1979;49:507-513.
26. Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev. 1996;17:121-155.
27. Shaw ND, Klingman KM, Srouji SS, Histed SN, Hall JE. Gonadotropin responses to estrogen-positive and -negative feedback are identical in African-American and Caucasian women. J Clin Endocrinol Metab. 2012;97:E106-E109.
28. Apter D, Raisanen I, Ylostalo P, Vihko R. Follicular growth in relation to serum hormonal patterns in adolescent compared with adult menstrual cycles. Fertil Steril. 1987;47:82-88.
29. Venturoli S, Porcu E, Fabbri R, et al. Menstrual irregularities in adolescents: hormonal pattern and ovarian morphology.HormRes. 1986;24:269-279.
30. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. Hum Reprod. 1999;14:2223-2229.
31. Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab. 1984;58:378-383.
32. Soules MR, Steiner RA, Clifton DK, Bremner WJ. Abnormal patterns of pulsatile luteinizing hormone in women with luteal phase deficiency. Obstet Gynecol. 1984;63:626-629.
33. Soules MR, Steiner RA, Cohen NL, Bremner WJ, Clifton DK. Nocturnal slowing of pulsatile luteinizing hormone secretion in women during the follicular phase of the menstrual cycle. J Clin Endocrinol Metab. 1985;61:43-49.
34. McCartney CR, Blank SK, Marshall JC. Progesterone acutely increasesLHpulse amplitude but does not acutely influence nocturnal LH pulse frequency slowing during the late follicular phase in women. Am J Physiol Endocrinol Metab. 2007;292:E900-E906.
35. Shaw ND, Gill S, Lavoie HB, Marsh EE, Hall JE. Persistence of sleep-Associated decrease inGnRHpulse frequency in the absence of gonadal steroids. J Clin Endocrinol Metab. 2011;96:2590-2595.
36. Kapen S, Boyar R, Hellman L, Weitzman ED. The relationship of luteinizing hormone secretion to sleep in women during the early follicular phase: effects of sleep reversal and a prolonged three-hour sleep-wake schedule. J Clin Endocrinol Metab. 1976;42:1031-1040.
37. McCartney CR, Gingrich MB, Hu Y, Evans WS, Marshall JC. Hypothalamic regulation of cyclic ovulation: evidence that the increase in gonadotropin-releasing hormone pulse frequency during the follicular phase reflects the gradual loss of the restraining effects of progesterone. J Clin Endocrinol Metab. 2002;87:2194-2200.
38. Klingman KM, Marsh EE, Klerman EB, Anderson EJ, Hall JE. Absence of circadian rhythms of gonadotropin secretion in women. J Clin Endocrinol Metab. 2011;96:1456-1461.
39. Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2248-2256.
40. Caronia LM, Martin C, Welt CK, et al.Agenetic basis for functional hypothalamic amenorrhea. N Engl J Med. 2011;364:215-225.
41. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science. 1974;185:949-951.
42. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351: 987-997.
43. Marshall JC, Kelch RP. Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction. N Engl J Med. 1986;315:1459-1468.
44. Perkins RB, Hall JE, Martin KA. Neuroendocrine abnormalities in hypothalamic amenorrhea: spectrum, stability, and response to neurotransmitter modulation. J Clin Endocrinol Metab. 1999;84: 1905-1911.
45. Katz JL, Boyar R, Roffwarg H, Hellman L, Weiner H. Weight and circadian luteinizing hormone secretory pattern in anorexia nervosa. Psychosom Med. 1978;40:549-567.
46. Jain A, Polotsky AJ, Rochester D, et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab. 2007;92:2468-2473.
47. Rochester D, Jain A, Polotsky AJ, et al. Partial recovery of luteal function after bariatric surgery in obese women. Fertil Steril. 2009; 92:1410-1415.
48. Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res. 2010;1364:186-197.
49. Zimmer CA, Ehrmann DA, Rosenfield RL. Potential diagnostic utility of intermittent administration of short-Acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. Fertil Steril. 2010;94:2697-2702.
50. Aono T, Miyake A, Kinugasa T, Kurachi K, Matsumoto K. Absence of positive feedback effect of oestrogen on LH release in patients with testicular feminization syndrome. Acta Endocrinol (Copenh). 1978;87:259-267.
51. Foecking EM, Szabo M, Schwartz NB, Levine JE. Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod. 2005;72:1475-1483.
52. Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin- releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 2000;85:4047-4052.
53. Blank SK, McCartney CR, Chhabra S, et al. Modulation of gonadotropin- releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls-implications for regulation of pubertal maturation. J Clin Endocrinol Metab. 2009;94:2360-2366.
54. Porcu E, Venturoli S, Magrini O, et al. Circadian variations of luteinizing hormone can have two different profiles in adolescent anovulation. J Clin Endocrinol Metab. 1987;65:488-493.
55. Venturoli S, Porcu E, Fabbri R, et al. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. J Clin Endocrinol Metab. 1992;74:836-841.
56. Venturoli S, Porcu E, Fabbri R, et al. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res. 1995;38:974-980.
57. Apter D, Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J Clin Endocrinol Metab. 1990;71:970-974.
58. Rosenfield RL, Cooke DW, Radovick S. The ovary and female maturation. In: Sperling M, ed. Pediatric Endocrinology. 3rd ed. Philadelphia, PA: Elsevier; 2008:530-609.
59. Misra M. Long-term skeletal effects of eating disorders with onset in adolescence. Ann NY Acad Sci. 2008;1135:212-218.
60. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28-38.e25.
61. Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med. 2012;366:443-453.
62. Sykiotis GP, Plummer L, Hughes VA, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci USA. 2010;107:15140-15144.
63. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-462.
64. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950womenreferred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2-6.
65. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995;16:322-353.
66. Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, Ehrmann DA. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011;26:3138-3146.
67. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999; 13:946-957.
68. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004;10:107-117.
69. Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:787-796.
70. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond). 2008;32:1035-1041.
71. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-191.
72. Johnson T, Kaplan L, Ouyang P, Rizza R. National Institutes of Health Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome (PCOS). http://prevention.nih.gov/workshops/ 2012/pcos/default.aspx. Published December 3-5, 2012. Accessed July 27, 2013.
73. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
74. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456-488.
75. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-Amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66:513-517.
76. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94:2197-2201.
77. Panidis D, Tziomalos K, Misichronis G, et al. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod. 2012;27:541-549.
78. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G, eds. Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific Publications; 1992:377-384.
79. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012;98:242-249.
80. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203: 201.e1-e5.
81. Mortensen M, Rosenfield RL, Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. J Clin Endocrinol Metab. 2006;91:3786-3790.
82. Mortensen M, Ehrmann DA, Littlejohn E, Rosenfield RL. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009;94: 1579-1586.
83. Rosenfield RL, Ghai K, Ehrmann DA, Barnes RB. Diagnosis of polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab. 2000;13(suppl 5):1285-1289.
84. Apter D, Bützow T, Laughlin GA, Yen SS. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab. 1994;79: 119-125.
85. Codner E, Villarroel C, Eyzaguirre FC, et al. Polycystic ovarian morphology in postmenarchal adolescents. Fertil Steril. 2011;95: 702-706.e1-e2.
86. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505-514.
87. Johnstone EB, Rosen MP, Neril R, et al. The polycystic ovary post- Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab. 2010;95: 4965-4972.
88. Bentzen JG, Forman JL, Johannsen TH, Pinborg A, Larsen EC, Andersen AN. Ovarian antral follicle subclasses and anti-Mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab. 2013;98:1602-1611.
89. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492-497.
90. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab. 2006;91:1275-1283.
91. Rossi B, Sukalich S, Droz J, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93: 4780-4786.
92. Nandalike K, Strauss T, Agarwal C, et al. Screening for sleep-disordered breathing and excessive daytime sleepiness in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2011;159:591-596.
93. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001;138:38-44.
94. Apter D, Butzow T, Laughlin GA, Yen SS. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab. 1995;80:2966-2973.
95. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009;94:157-163.
96. Du X, Rosenfield RL, Qin K. KLF15 is a transcriptional regulator of the human 17-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. J Clin Endocrinol Metab. 2009;94:2594-2601.
97. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90:2545-2549.
98. Robinson S, Kiddy D, Gelding S, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf). 1993;39:351-355.
99. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;36:105-111.
100. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470-1474.
101. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876-1880.
102. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;3:CD003053.
103. Ehrmann D, Schneider D, Sobel B, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-2116.
104. Bloch CA, Clemons P, Sperling MA. Puberty decreases insulin sensitivity. J Pediatr. 1987;110:481-487.
105. Caprio S, Jones T, Tamborlane W. Developmental changes in insulin action and secretion in childhood health and disease. Adv Endocrinol Metab. 1994;5:171-201.
106. Caprio S. Insulin: the other anabolic hormone of puberty. Acta Paediatr Suppl. 1999;88:84-87.
107. Moran A, Jacobs DR Jr, Steinberger J, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes. 1999;48:2039-2044.
108. Cara JF, Rosenfield RL, FurlanettoRW.Alongitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. Am J Dis Child. 1987;141:562-564.
109. Clark PA, Rogol AD. Growth hormones and sex steroid interactions at puberty. Endocrinol Metab Clin NorthAm. 1996;25:665-681.
110. Braverman PK, Breech L. American Academy of Pediatrics. Clinical report- gynecologic examination for adolescents in the pediatric office setting. Pediatrics. 2010;126:583-590.
111. Rebar R, Connolly H. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril. 1990;53:804-810.
112. Futterweit W, Deligdisch L. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab. 1986;62:16-21.
113. Benjamins LJ. Practice guideline: evaluation and management of abnormal vaginal bleeding in adolescents. J Pediatr Health Care. 2009;23:189-193.
114. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93: 1105-1120.
115. Wartofsky L, Handelsman DJ. Standardization of hormonal assays for the 21st century. J Clin Endocrinol Metab. 2010;95:5141-5143.
116. Liu JH, Bill AH. Stress-Associated or functional hypothalamic amenorrhea in the adolescent. AnnNYAcad Sci. 2008;1135:179-184.
117. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab. 2005;90:6424-6430.
118. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med. 2011;364:1230-1242.
119. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. 2010;8:979-986.
120. MisraM,Klibanski A. Bone health in anorexia nervosa. Curr Opin Endocrinol Diabetes Obes. 2011;18:376-382.
121. Torres-Santiago L, Mericq V, Taboada M, et al. Metabolic effects of oral versus transdermal 17 estradiol (E2): a randomized clinical trial in girls with Turner syndrome. J Clin Endocrinol Metab. 2013; 98:2716-2724.
122. Bondy CA. Care of girls and women with Turner syndrome: a guideline of the Turner syndrome study group. J Clin Endocrinol Metab. 2007;92:10-25.
123. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow- up study. BMJ. 2009;339:b2890.
124. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151.
125. US Food and Drug Administration. Updated external questions and answers-ongoing safety review of birth control pills containing drospirenoneandapossible increased risk ofbloodclots. http://www.fda- .gov/Drugs/DrugSafety/ucm299348.htm. Published May 31, 2011. Updated April 10, 2012. Accessed July 27, 2013.
126. Gordon CM, Pitts SA. Approach to the adolescent requesting contraception. J Clin Endocrinol Metab. 2012;97:9-15.
127. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009;92:1966-1982.
128. Geller DH, Pacaud D, Gordon CM, Misra M. State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol. 2011;2011:9.
129. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006;21: 80-89.
130. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulinsensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;5: CD003053.
131. Levine RJ, Genel M, Cuttler L, Becker DJ, Nieman L, Rosenfield RL. Overcoming burdens in the regulation of clinical research in children. Proceedings of a consensus conference, in historical context. Int J Pediatr Endocrinol. 2011;2011:19.
132. ACOGCommittee on Adolescent Health Care.ACOGCommittee Opinion No. 349, November 2006: Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol. 2006;108:1323-1328.